scholarly journals Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report

2021 ◽  
Author(s):  
Heather Perkins ◽  
Robert J. Klaassen
Keyword(s):  
Case Report ◽  
Laparoscopic Appendectomy ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Fvii Deficiency

scholarly journals Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report

2020 ◽  
Author(s):  
Robert Klaassen ◽  
Heather Perkins
Keyword(s):  
Laparoscopic Appendectomy ◽  
Perioperative Management ◽  
Healthcare Providers ◽  
Factor Vii ◽  
Severe Bleeding ◽  
Bleeding Disorders ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Hospital Resources ◽  
Fvii Deficiency

Surgery in patients with factor VII (FVII) deficiency may be complicated by severe bleeding, requiring regular bolus doses of replacement therapy. Eptacog alfa (activated) is a recombinant activated FVII (rFVIIa) used for the treatment of bleeds and perioperative management in patients with approved bleeding disorders, including FVII deficiency. We report that using the B-Braun Perfusor® Space syringe pump to automatically deliver regular bolus rFVIIa doses provided effective hemostasis and no safety concerns in a patient with mild FVII deficiency undergoing emergency laparoscopic appendectomy. Additional benefits included saving nursing/hospital resources, reducing treatment burden and reassurance for the patient/family, and healthcare providers.

scholarly journals Congenital Deficiency in Factor VII Revealed by Menorrhagia: Case Report

2020 ◽  
pp. 1-5
Author(s):  
Nadia Mebrouk ◽  
Abdelilah Radi ◽  
Mohamed Selouti ◽  
Amal Hassani ◽  
Abdelhakim Ourrai ◽  
...  
Keyword(s):  
Treatment Options ◽  
Specific Treatment ◽  
Fresh Frozen Plasma ◽  
Factor Vii ◽  
Activity Measurement ◽  
Recombinant Activated Factor Vii ◽  
Congenital Deficiency ◽  
Activated Factor Vii ◽  
Fresh Frozen ◽  
Fvii Deficiency

Factor VII (FVII) deficiency is the most common among rare inherited autosomal recessive bleeding disorders. It is a multifaceted disease because of the lack of a direct correlation between plasma levels of coagulation FVII and bleeding manifestations. Clinical phenotypes range from asymptomatic condition—even in homozygous subjects—to severe, life-threatening bleedings (e.g., central nervous system and gastrointestinal bleeding). Menorrhagia is a frequent type of bleeding in FVII deficiency, with a prevalence rate of two in three women aged 10 to 50 years and with a peak prevalence in teenagers. When menorrhagia is observed and once the gynecological causes are excluded, it is important to carry out a hemostasis assessment because, if an anomaly is found, specific treatment can be administered and preventive measures taken. Basic diagnostic work-up includes routine assays, prothrombin level, activated partial thromboplastin time and platelet count, followed by FVII coagulant activity measurement for isolated decreased prothrombin level. To confirm the diagnosis, FVII assay should be repeated at least once. Several treatment options are currently available for FVII deficiency: Recombinant activated Factor VII (rFVIIa), plasma-derived Factor VII, fresh frozen plasma and prothrombin complex concentrates. rFVIIa is the most used replacement therapy. Other medical therapies of menorrhagia includes hemostatic agents and hormonal treatments (combined oral contraceptives, levonorgestrel intrauterine devices), in combination or not with rFVIIa. We report the case of a fourteen-and-a-half-year-old girl who presented menorrhagia of great abundance at the age of thirteen, the exploration of which revealed a congenital deficit in FVII.

Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report

2011 ◽  
Vol 69 (6) ◽  
pp. 713-719
Author(s):  
Jean-François Comes ◽  
Jean Devignes ◽  
Olivier Thiebaugeorges ◽  
Marie-Elisabeth Briquel ◽  
Thomas Lecompte
Keyword(s):  
Case Report ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Factor Vii Deficiency ◽  
Activated Factor Vii ◽  
Prophylactic Use

Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

2005 ◽  
Vol 94 (12) ◽  
pp. 1177-1180 ◽  
Author(s):  
Geir E. Tjønnfjord ◽  
Richard Wallensten ◽  
Uri Martinowitz ◽  
Gili Kenet ◽  
Sam Schulman
Keyword(s):  
Continuous Infusion ◽  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Single Case ◽  
Thromboembolic Complication ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Different Types ◽  
Fvii Deficiency

SummaryThe administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factorVII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.

Sign in / Sign up

Export Citation Format

Share Document